$MRKR
Marker Therapeutics, Inc.

2021 Q3 Form 10-K Financial Statement

#000141057822000418 Filed on March 17, 2022

View on sec.gov

Income Statement

Concept 2021 Q3 2021 Q2 2021
Revenue $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.239M $3.559M $12.92M
YoY Change 26.04% 39.57% 23.45%
% of Gross Profit
Research & Development $6.784M $7.350M $27.79M
YoY Change 41.24% 71.85% 47.21%
% of Gross Profit
Depreciation & Amortization $600.0K $500.0K $2.149M
YoY Change 500.0% 400.0% 342.5%
% of Gross Profit
Operating Expenses $10.02M $10.91M $40.72M
YoY Change 35.89% 59.86% 38.73%
Operating Profit -$10.02M -$10.91M -$39.48M
YoY Change 35.89% 71.59% 36.67%
Interest Expense $790.00 $2.400K $5.700K
YoY Change -88.0% -96.83%
% of Operating Profit
Other Income/Expense, Net $2.400M $2.400M
YoY Change
Pretax Income -$12.43M -$10.91M -$41.88M
YoY Change 68.65% 72.03% 45.87%
Income Tax
% Of Pretax Income
Net Earnings -$12.43M -$10.91M -$41.88M
YoY Change 68.61% 71.99% 45.89%
Net Earnings / Revenue
Basic Earnings Per Share -$0.15 -$0.13 -$0.55
Diluted Earnings Per Share -$149.6K -$0.13 -$0.55
COMMON SHARES
Basic Shares Outstanding 83.08M 83.03M 76.51M
Diluted Shares Outstanding 83.08M 83.03M 76.51M

Balance Sheet

Concept 2021 Q3 2021 Q2 2021
SHORT-TERM ASSETS
Cash & Short-Term Investments $48.71M $57.22M $42.35M
YoY Change 80.66% 78.15% 98.37%
Cash & Equivalents $48.70M $57.20M $42.35M
Short-Term Investments
Other Short-Term Assets $2.701M $2.802M $3.631M
YoY Change 13.98% 6.53% 76.25%
Inventory
Prepaid Expenses $2.701M $2.802M
Receivables
Other Receivables $243.00 $1.000M
Total Short-Term Assets $51.41M $60.02M $45.98M
YoY Change 69.53% 72.68% 88.37%
LONG-TERM ASSETS
Property, Plant & Equipment $10.45M $10.11M $22.15M
YoY Change 45.36% 139.47% 4.49%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $20.53M $20.45M $22.15M
YoY Change 12.53% 48.56% 4.49%
TOTAL ASSETS
Total Short-Term Assets $51.41M $60.02M $45.98M
Total Long-Term Assets $20.53M $20.45M $22.15M
Total Assets $71.94M $80.47M $68.14M
YoY Change 48.11% 65.84% 49.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.326M $2.042M $5.144M
YoY Change -37.07% -27.28% 74.97%
Accrued Expenses $2.674M $2.409M $3.569M
YoY Change 39.25% 17.5% 16.65%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $8.227M $5.660M $12.90M
YoY Change 36.56% 13.55% 101.59%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $11.43M $11.57M $11.25M
YoY Change -4.34% 28.11% -5.24%
Total Long-Term Liabilities $11.43M $11.57M $11.25M
YoY Change -4.33% 28.17% -5.24%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.227M $5.660M $12.90M
Total Long-Term Liabilities $11.43M $11.57M $11.25M
Total Liabilities $19.66M $17.23M $24.15M
YoY Change 9.37% 22.97% 32.18%
SHAREHOLDERS EQUITY
Retained Earnings -$388.4M -$375.9M
YoY Change 11.68% 10.45%
Common Stock $83.08K $83.08K
YoY Change 72.99% 78.22%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $52.28M $63.24M $43.99M
YoY Change
Total Liabilities & Shareholders Equity $71.94M $80.47M $68.14M
YoY Change 48.11% 65.84% 49.39%

Cashflow Statement

Concept 2021 Q3 2021 Q2 2021
OPERATING ACTIVITIES
Net Income -$12.43M -$10.91M -$41.88M
YoY Change 68.61% 71.99% 45.89%
Depreciation, Depletion And Amortization $600.0K $500.0K $2.149M
YoY Change 500.0% 400.0% 342.5%
Cash From Operating Activities -$7.536M -$5.826M -$27.28M
YoY Change 77.73% 35.48% 36.16%
INVESTING ACTIVITIES
Capital Expenditures -$980.3K -$1.361M -$3.131M
YoY Change -68.48% -64.46% -69.98%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$980.3K -$1.361M -$3.131M
YoY Change -68.48% -64.46% -66.16%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $52.55M
YoY Change 749.54%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 -104.1K 52.56M
YoY Change -100.0% 680.22%
NET CHANGE
Cash From Operating Activities -7.536M -5.826M -27.28M
Cash From Investing Activities -980.3K -1.361M -3.131M
Cash From Financing Activities 0.000 -104.1K 52.56M
Net Change In Cash -8.516M -7.291M 43.50M
YoY Change 65.04% -10.32% -292.89%
FREE CASH FLOW
Cash From Operating Activities -$7.536M -$5.826M -$27.28M
Capital Expenditures -$980.3K -$1.361M -$3.131M
Free Cash Flow -$6.556M -$4.465M -$24.15M
YoY Change 480.14% 849.95% 151.43%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.55
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.61
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
76505675
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47039862
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
76505675
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47039862
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.55
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.61
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
11134913
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
6013010
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001094038
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
83100000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9830461
CY2020 mrkr Payments For Construction In Progress
PaymentsForConstructionInProgress
5830133
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
50700000
CY2021Q4 us-gaap Deferred Revenue
DeferredRevenue
1100000
CY2021Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1100000
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-37939
CY2021 dei Entity Registrant Name
EntityRegistrantName
MARKER THERAPEUTICS, INC.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-4497941
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
3200 Southwest Freeway
CY2021 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 2500
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Houston
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77027
CY2021 dei City Area Code
CityAreaCode
713
CY2021 dei Local Phone Number
LocalPhoneNumber
400-6400
CY2021 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2021 dei Trading Symbol
TradingSymbol
MRKR
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
164300000
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
83078675
CY2021 dei Auditor Firm
AuditorFirmId
688
CY2021 dei Auditor Name
AuditorName
Marcum LLP
CY2021 dei Auditor Location
AuditorLocation
Houston TX
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42351145
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21352382
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
1146186
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2484634
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2057924
CY2021Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
237
CY2020Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
1000559
CY2021Q4 us-gaap Assets Current
AssetsCurrent
45982202
CY2020Q4 us-gaap Assets Current
AssetsCurrent
24410865
CY2021Q4 mrkr Property Plant And Equipment Other Than Construction In Progress
PropertyPlantAndEquipmentOtherThanConstructionInProgress
10096861
CY2020Q4 mrkr Property Plant And Equipment Other Than Construction In Progress
PropertyPlantAndEquipmentOtherThanConstructionInProgress
3570736
CY2021Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
2225610
CY2020Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
6789098
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10844116
CY2021Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
22152932
CY2020Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
21203950
CY2021Q4 us-gaap Assets
Assets
68135134
CY2020Q4 us-gaap Assets
Assets
45614815
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
11134913
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
6013010
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
620490
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
388792
CY2021Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1146186
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12901589
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6401802
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
11247950
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
11868440
CY2021Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
11247950
CY2020Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
11868440
CY2021Q4 us-gaap Liabilities
Liabilities
24149539
CY2020Q4 us-gaap Liabilities
Liabilities
18270242
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
83100000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
50700000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
83079
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
50731
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
442020871
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
383533326
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-398118355
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-356239484
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
43985595
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
27344573
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
68135134
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
45614815
CY2021 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1241710
CY2020 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
466785
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27794879
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18880751
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12924826
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10471846
CY2021 us-gaap Operating Expenses
OperatingExpenses
40719705
CY2020 us-gaap Operating Expenses
OperatingExpenses
29352597
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-39477995
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-28885812
CY2020 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
31000
CY2021 mrkr Gain Loss Related To Arbitration Settlement
GainLossRelatedToArbitrationSettlement
-2406576
CY2021 us-gaap Investment Income Interest
InvestmentIncomeInterest
5700
CY2020 us-gaap Investment Income Interest
InvestmentIncomeInterest
148742
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-41878871
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-28706070
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.55
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.61
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76505675
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47039862
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
44086223
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
6186011
CY2020 mrkr Exercise Of Warrants Amount
ExerciseOfWarrantsAmount
550000
CY2020 mrkr Issuance Of Common Stock Value As Commitment Fee For Future Financing
IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing
0
CY2020 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
5228409
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-28706070
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
27344573
CY2021 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
3900000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
52552758
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3087
CY2021 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
5964048
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-41878871
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
43985595
CY2021 us-gaap Profit Loss
ProfitLoss
-41878871
CY2020 us-gaap Profit Loss
ProfitLoss
-28706070
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2148983
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
485641
CY2020 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-31000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
5964048
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
5228409
CY2021 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1013655
CY2020 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
590039
CY2021 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
426710
CY2020 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
531482
CY2021 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-1000322
CY2020 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-55630
CY2021 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
4141414
CY2020 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3047410
CY2021 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1146186
CY2021 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-388792
CY2020 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-173268
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27279765
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20034691
CY2021 mrkr Payments To Acquire Property Plant And Equipment Excluding Construction In Progress
PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress
1572161
CY2020 mrkr Payments To Acquire Property Plant And Equipment Excluding Construction In Progress
PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress
3422754
CY2021 mrkr Payments For Construction In Progress
PaymentsForConstructionInProgress
1558970
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3131131
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-9252887
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
52552758
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6186011
CY2020 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
550000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3087
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
52555845
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6736011
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
22144949
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-22551567
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21352382
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43903949
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43497331
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21352382
CY2021 mrkr Reclassifications Between Construction In Progress And Fixed Assets
ReclassificationsBetweenConstructionInProgressAndFixedAssets
6789098
CY2021 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2160765
CY2020 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1180276
CY2021 mrkr Non Cash Issuance Of Common Stock As Commitment Fee For Future Financing
NonCashIssuanceOfCommonStockAsCommitmentFeeForFutureFinancing
0
CY2020 mrkr Non Cash Issuance Of Common Stock As Commitment Fee For Future Financing
NonCashIssuanceOfCommonStockAsCommitmentFeeForFutureFinancing
345
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
11114300
CY2021 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 1:    NATURE OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Marker Therapeutics, Inc., a Delaware corporation (the “Company” or “we”), is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The Company’s MultiTAA-specific T cell technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, which are tumor targets, and kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. The Company was incorporated in Nevada in 1992 and reincorporated in Delaware in October 2018.</p>
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
43500000
CY2021Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
32282857
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
52600000
CY2021Q3 us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
13100000
CY2021Q3 mrkr Funds Received From Cprit Grant
FundsReceivedFromCpritGrant
2400000
CY2021 mrkr Revenue From Grant Related To Cprit
RevenueFromGrantRelatedToCprit
1200000
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
1100000
CY2021 us-gaap Comparability Of Prior Year Financial Data
ComparabilityOfPriorYearFinancialData
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Prior Period Reclassification</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Certain reclassifications have been made to reclass certain non-cash capital expenditures on the consolidated statements of cash flows from a cash outflow from investing activity to a non-cash investing activity. The Company has evaluated the materiality of this adjustment and concluded it was not material to the previously issued consolidated financial statements and had no impact to the reported consolidated balance sheets, consolidated statements of operations or net loss per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For the year ended December 31, 2020, this immaterial adjustment had the effect of increasing net cash used in operating activities and decreasing net cash used in investing activities by $1.2 million from what was previously reported.</p>
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Preparation of the Company’s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ materially from those estimates. Significant areas requiring management’s estimates and assumptions include valuation allowance on deferred tax assets, determining the fair value of stock-based compensation and stock-based transactions, the fair value of the components of the warrant liabilities and accrued liabilities.</p>
CY2021Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2021Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
3200000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42351145
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21352382
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
1146186
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43497331
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21352382
CY2021 us-gaap Property Plant And Equipment Estimated Useful Lives
PropertyPlantAndEquipmentEstimatedUsefulLives
the straight-line method over the estimated useful lives of the related assets, which range from three to five years
CY2021Q4 mrkr Restricted Cash And Investment
RestrictedCashAndInvestment
1100000
CY2021Q3 mrkr Receipt Of Product Development Research Award
ReceiptOfProductDevelopmentResearchAward
13100000
CY2021Q4 mrkr Funds Received From Cprit Grant
FundsReceivedFromCpritGrant
2400000
CY2021 mrkr Revenue From Grant Related To Cprit
RevenueFromGrantRelatedToCprit
1200000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-41878871
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-28706070
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76505675
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47039862
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.55
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.61
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
27516000
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
26832000
CY2021Q4 us-gaap Tenant Improvements
TenantImprovements
1000000.0
CY2020Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
1000000.0
CY2021Q2 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
1000000.0
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12837000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4162000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2740000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
591000
CY2021Q4 mrkr Construction In Progress
ConstructionInProgress
2226000
CY2020Q4 mrkr Construction In Progress
ConstructionInProgress
6789000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12323000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10360000
CY2021 us-gaap Depreciation
Depreciation
2100000
CY2020 us-gaap Depreciation
Depreciation
500000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
11900000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9800000
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
1702000
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
960000
CY2020 us-gaap Short Term Lease Cost
ShortTermLeaseCost
22000
CY2021 us-gaap Variable Lease Cost
VariableLeaseCost
606000
CY2020 us-gaap Variable Lease Cost
VariableLeaseCost
167000
CY2021 us-gaap Lease Cost
LeaseCost
2308000
CY2020 us-gaap Lease Cost
LeaseCost
1149000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
1077000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
544000
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y4M24D
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y3M18D
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.057
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.057
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1278000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1542000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1826000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1874000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
1775000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
6997000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
15292000
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
3424000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
11868000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5144000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2935000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2055000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1694000
CY2021Q4 mrkr Accrued Process Development Expenses Current
AccruedProcessDevelopmentExpensesCurrent
385000
CY2020Q4 mrkr Accrued Process Development Expenses Current
AccruedProcessDevelopmentExpensesCurrent
277000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
644000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
875000
CY2021Q4 mrkr Accrued Technology License Fees
AccruedTechnologyLicenseFees
250000
CY2020Q4 mrkr Accrued Technology License Fees
AccruedTechnologyLicenseFees
105000
CY2021Q4 mrkr Arbitration Settlement Liabilities Current
ArbitrationSettlementLiabilitiesCurrent
2407000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
250000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
127000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
22664000
CY2019Q4 mrkr Class Of Warrant Or Rights Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice
4.71
CY2019 mrkr Class Of Warrant Or Rights Outstanding Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife
P3Y3M29D
CY2019Q4 mrkr Class Of Warrant Or Right Outstanding Intrinsic Value
ClassOfWarrantOrRightOutstandingIntrinsicValue
954000
CY2020 mrkr Number Of Warrant Exercised For Cash
NumberOfWarrantExercisedForCash
458000
CY2020 mrkr Class Of Warrant Or Rights Outstanding Exercised Weighted Average Exercised For Cash
ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisedForCash
1.20
CY2020 mrkr Number Of Warrant Expired Or Cancelled
NumberOfWarrantExpiredOrCancelled
1376000
CY2020 mrkr Class Of Warrant Or Rights Outstanding Expired Or Cancelled Weighted Average Exercise Price
ClassOfWarrantOrRightsOutstandingExpiredOrCancelledWeightedAverageExercisePrice
9.46
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
20830000
CY2020Q4 mrkr Class Of Warrant Or Rights Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice
4.47
CY2020 mrkr Class Of Warrant Or Rights Outstanding Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife
P2Y7M6D
CY2021 mrkr Number Of Warrant Expired Or Cancelled
NumberOfWarrantExpiredOrCancelled
1000000
CY2021 mrkr Class Of Warrant Or Rights Outstanding Expired Or Cancelled Weighted Average Exercise Price
ClassOfWarrantOrRightsOutstandingExpiredOrCancelledWeightedAverageExercisePrice
5.50
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
19830000
CY2021Q4 mrkr Class Of Warrant Or Rights Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice
4.42
CY2021 mrkr Class Of Warrant Or Rights Outstanding Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife
P1Y8M12D
CY2020Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
500000
CY2020 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
600000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6001814
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.22
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y3M18D
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1915000
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.90
CY2021 mrkr Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted In Period Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm
P8Y10M24D
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1456
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.12
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
229125
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.59
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.08
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7686233
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.47
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y8M12D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4298747
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.66
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y2M12D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
2.90
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
2.08
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.94
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.01
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.01
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5964000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5228000
CY2021Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
8600000
CY2021 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y
CY2021 us-gaap Revenues
Revenues
0
CY2020 us-gaap Revenues
Revenues
500000
CY2021Q3 mrkr Receipt Of Product Development Research Award
ReceiptOfProductDevelopmentResearchAward
13100000
CY2021 mrkr Funds Received From Grant
FundsReceivedFromGrant
2400000
CY2021 mrkr Revenue From Grant Related To Cprit
RevenueFromGrantRelatedToCprit
1200000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
1100000
CY2021 mrkr Compensation Interest And Attorney Fees
CompensationInterestAndAttorneyFees
2400000
CY2021Q3 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
2400000
CY2021Q3 us-gaap Other Expenses
OtherExpenses
2400000
CY2022Q1 mrkr Legal Proceedings Broker Awarded Additional Interest Amount
LegalProceedingsBrokerAwardedAdditionalInterestAmount
100000
CY2022Q1 mrkr Percentage Of Accrual Of Post Judgment Interest
PercentageOfAccrualOfPostJudgmentInterest
0.0102
CY2021 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
3437000
CY2020 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
2031000
CY2021Q4 us-gaap Due To Related Parties Current And Noncurrent
DueToRelatedPartiesCurrentAndNoncurrent
1000000.0
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
29087000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
21783000
CY2021Q4 mrkr Deferredtaxstockbasedcompensation
Deferredtaxstockbasedcompensation
5599000
CY2020Q4 mrkr Deferredtaxstockbasedcompensation
Deferredtaxstockbasedcompensation
6775000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
510000
CY2021Q4 mrkr Deferredtaxassetslicenseagreement
Deferredtaxassetslicenseagreement
127000
CY2020Q4 mrkr Deferredtaxassetslicenseagreement
Deferredtaxassetslicenseagreement
144000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
733000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
733000
CY2021Q4 us-gaap Deferred Tax Assets Charitable Contribution Carryforwards
DeferredTaxAssetsCharitableContributionCarryforwards
8000
CY2020Q4 us-gaap Deferred Tax Assets Charitable Contribution Carryforwards
DeferredTaxAssetsCharitableContributionCarryforwards
8000
CY2021Q4 mrkr Deferred Tax Assets Operating Lease Liability
DeferredTaxAssetsOperatingLeaseLiability
2514000
CY2020Q4 mrkr Deferred Tax Assets Operating Lease Liability
DeferredTaxAssetsOperatingLeaseLiability
2626000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
38578000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
32069000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
36401000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
29689000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
2177000
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.0236
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
2380000
CY2021Q4 mrkr Deferred Tax Liabilities Fixed Assets
DeferredTaxLiabilitiesFixedAssets
94000
CY2021Q4 mrkr Deferred Tax Liabilities Right Of Use Assets
DeferredTaxLiabilitiesRightOfUseAssets
2083000
CY2020Q4 mrkr Deferred Tax Liabilities Right Of Use Assets
DeferredTaxLiabilitiesRightOfUseAssets
2380000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
2177000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
2380000
CY2021 mrkr Decreased Deferred Tax Assets
DecreasedDeferredTaxAssets
-2100000
CY2021 mrkr Decreased Deferred Tax Assets
DecreasedDeferredTaxAssets
-2100000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
733000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
130500000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
38600000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
41600000
CY2021 mrkr Taxcreditcarryforwardexpirationyearrangestart
Taxcreditcarryforwardexpirationyearrangestart
2029
CY2021 mrkr Taxcreditcarryforwardexpirationyearrangeend
Taxcreditcarryforwardexpirationyearrangeend
2037
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
21900000
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-8795000
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-6028000
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2021 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-48000
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0011
CY2020 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-118000
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0041
CY2021 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
-291000
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.0069
CY2020 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
677000
CY2021 mrkr Effective Income Tax Rate Reconciliation Change In Fair Value Of Derivative Liability
EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability
0.0000
CY2020 mrkr Incometaxreconciliationchangeinfairvalueofderivativeliability
Incometaxreconciliationchangeinfairvalueofderivativeliability
-7000
CY2020 mrkr Effective Income Tax Rate Reconciliation Change In Fair Value Of Derivative Liability
EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability
0.0002
CY2021 mrkr Permanentdifferencesotherpermanentdifferences
Permanentdifferencesotherpermanentdifferences
-262000
CY2021 mrkr Effective Income Tax Rate Reconciliation Other Permanent Differences
EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences
-0.0063
CY2020 mrkr Permanentdifferencesotherpermanentdifferences
Permanentdifferencesotherpermanentdifferences
-182000
CY2020 mrkr Effective Income Tax Rate Reconciliation Other Permanent Differences
EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences
-0.0063
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-8769000
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2094
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-5057000
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.1762
CY2021 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
103000
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0025
CY2020 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
237000
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0083
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0

Files In Submission

Name View Source Status
0001410578-22-000418-index-headers.html Edgar Link pending
0001410578-22-000418-index.html Edgar Link pending
0001410578-22-000418.txt Edgar Link pending
0001410578-22-000418-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
mrkr-20211231.xsd Edgar Link pending
mrkr-20211231x10k.htm Edgar Link pending
mrkr-20211231x10k001.jpg Edgar Link pending
mrkr-20211231x10k002.jpg Edgar Link pending
mrkr-20211231x10k003.jpg Edgar Link pending
mrkr-20211231x10k004.jpg Edgar Link pending
mrkr-20211231x10k005.jpg Edgar Link pending
mrkr-20211231x10k006.jpg Edgar Link pending
mrkr-20211231x10k007.jpg Edgar Link pending
mrkr-20211231x10k008.jpg Edgar Link pending
mrkr-20211231x10k009.jpg Edgar Link pending
mrkr-20211231x10k010.jpg Edgar Link pending
mrkr-20211231x10k011.jpg Edgar Link pending
mrkr-20211231x10k_htm.xml Edgar Link completed
mrkr-20211231xex21d1.htm Edgar Link pending
mrkr-20211231xex23d1.htm Edgar Link pending
mrkr-20211231xex31d1.htm Edgar Link pending
mrkr-20211231xex31d2.htm Edgar Link pending
mrkr-20211231xex32d1.htm Edgar Link pending
mrkr-20211231xex32d2.htm Edgar Link pending
mrkr-20211231_cal.xml Edgar Link unprocessable
mrkr-20211231_def.xml Edgar Link unprocessable
mrkr-20211231_lab.xml Edgar Link unprocessable
mrkr-20211231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending